Cognition Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Cognition Therapeutics, Inc. (CGTX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.83 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-07
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 8.18M shares, a 3.28% increase year-over-year.
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 7.92M shares, a 41.13% increase year-over-year.
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 5.61M shares, a 25.64% increase year-over-year.
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 4.47M shares, a 12.57% decline year-over-year.
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 6.59M shares, a 19.18% increase from fiscal 2024.
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.53M shares, a 16.70% increase from fiscal 2023.
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.74M shares, a 28.70% increase from fiscal 2022.
- Cognition Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.68M shares, a 48.12% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 7.83M shares 10-Q · filed 2026-08-07 | ||||
| 2026-03-31 | 8.18M shares 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | 6.59M shares 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | 6.81M shares 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 7.38M shares 10-Q · filed 2026-08-07 | ||||
| 2025-03-31 | 7.92M shares 10-Q · filed 2026-05-08 | ||||
| 2024-12-31 | 5.53M shares 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | 5.57M shares 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 5.55M shares 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 5.61M shares 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | 4.74M shares 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | 4.71M shares 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | 4.69M shares 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 4.47M shares 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | 3.68M shares 10-K · filed 2024-03-26 | 6.45M shares 10-K · filed 2023-03-23 | |||
| 2022-09-30 | 3.73M shares 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | 5.23M shares 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 5.11M shares 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | 7.09M shares 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | 20.38M shares 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | 20.42M shares 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 17.19M shares 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | 17.73M shares 10-K · filed 2022-03-30 | 17.32M shares 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |